IDT Australia logo

IDT - IDT Australia Share Price

A$0.325 0.0  4.8%

Last Trade - 6:24am

Micro Cap
Market Cap £42.6m
Enterprise Value £38.6m
Revenue £7.02m
Position in Universe 977th / 1911
Unlock IDT Revenue
Relative Strength (%)
1m -6.61%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
15.7 7.60 9.54 13.3 12.1 14.2 20.6 20.5 -2.1%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, IDTAustralia Limited revenues decreased 20% to A$5.8M. Netincome totaled A$1.1M vs. loss of A$1.2M. Revenues reflectInterest received decrease of 57% to A$23K. Net Incomereflects Impairment of intangible assets decrease fromA$736K (expense) to A$0K, Depreciation and amortisationexpenses decrease of 27% to A$845K (expense), Employeebenefits expense decrease of 1% to A$3.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IDT Revenue Unlock IDT Revenue

Net Income

IDT Net Income Unlock IDT Revenue

Normalised EPS

IDT Normalised EPS Unlock IDT Revenue

PE Ratio Range

IDT PE Ratio Range Unlock IDT Revenue

Dividend Yield Range

IDT Dividend Yield Range Unlock IDT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IDT EPS Forecasts Unlock IDT Revenue
Profile Summary

IDT Australia Limited is engaged in the supply of products and provision of research and development and other technical services for the pharmaceutical and allied industries. The Company's segments include CMAX, Boronia and Corporate/Unallocated. Its CMAX is a clinical trial facility in Adelaide, South Australia. It has an integrated manufacturing, development and corporate facility at Boronia, Victoria. The Company specializes in manufacture of active pharmaceutical ingredients (API) and finished dose products, including beta lactams; microbiological and analytical testing; clinical packaging, and Phase I and first time in man clinical trials research and pharmacy services. Its IDT Pharma specializes in the development, scale-up and current goods manufacturing practices (cGMP) clinical and commercial manufacture of cytotoxic API and finished drug product. The Company also offers a range of clinical trial labelling, packaging and dispensing services.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated February 11, 1986
Public Since March 22, 1988
No. of Shareholders: 1,692
No. of Employees: 156
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 238,324,664
Free Float (0.0%)
Eligible for
IDT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDT
Upcoming Events for IDT
Frequently Asked Questions for IDT Australia
What is the IDT Australia share price?

As of 6:24am, shares in IDT Australia are trading at A$0.325, giving the company a market capitalisation of £42.6m. This share price information is delayed by 15 minutes.

How has the IDT Australia share price performed this year?

Shares in IDT Australia are currently trading at A$0.325 and the price has moved by 0.132k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IDT Australia price has moved by 73.74% over the past year.

What are the analyst and broker recommendations for IDT Australia?

Of the analysts with advisory recommendations for IDT Australia, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for IDT Australia is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will IDT Australia next release its financial results?

IDT Australia is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the IDT Australia dividend yield?

IDT Australia does not currently pay a dividend.

Does IDT Australia pay a dividend?

IDT Australia does not currently pay a dividend.

When does IDT Australia next pay dividends?

IDT Australia does not currently pay a dividend.

How do I buy IDT Australia shares?

To buy shares in IDT Australia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of IDT Australia?

Shares in IDT Australia are currently trading at A$0.325, giving the company a market capitalisation of £42.6m.

Where are IDT Australia shares listed? Where are IDT Australia shares listed?

Here are the trading details for IDT Australia:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: IDT
What kind of share is IDT Australia?

Based on an overall assessment of its quality, value and momentum, IDT Australia is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a IDT Australia share price forecast 2021?

We were not able to load any forecast data for IDT Australia.

How can I tell whether the IDT Australia share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDT Australia. Over the past six months, the relative strength of its shares against the market has been 66.78%. At the current price of A$0.325, shares in IDT Australia are trading at 49.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the IDT Australia PE Ratio?

The IDT Australia PE ratio based on its reported earnings over the past 12 months is 0.171k. The shares are currently trading at A$0.325.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of IDT Australia?

IDT Australia's management team is headed by:

Jane Kelly - VPR
David Sparling - CEO
Alan Fisher - CHM
Hugh Burrill - DRC
Mary Sontrop - NED
Michael Kotsanis - NID
Ancila Desai - CFO
Who are the major shareholders of IDT Australia?

Here are the top five shareholders of IDT Australia based on the size of their shareholding:

Sandon Capital Pty Ltd Investment Advisor
Percentage owned: 11.16% (26.8m shares)
Regal Funds Management Pty. Ltd. Hedge Fund
Percentage owned: 10.99% (26.4m shares)
I'rom Group Co Ltd Corporation
Percentage owned: 6.58% (15.8m shares)
One Managed Investment Funds Ltd. Corporation
Percentage owned: 6.25% (15.0m shares)
Huntley (Anthony John) Individual Investor
Percentage owned: 3.99% (9.58m shares)
Similar to IDT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.